SCHEMBL4723138

SCHEMBL4723138

O=Cc1ccc(NC(=O)c2csc(Cc3cc(Cl)ccc3OCc3ccccc3)n2)cc1

nearest known ligand 0.68

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 14/20 0.68
LMNA P02545 4/20 0.62
RAB9A P51151 3/20 0.62
ALDH1A1 P00352 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
L3MBTL1 Q9Y468 2/20 0.62
KMT2A Q03164 2/20 0.62
NPC1 O15118 2/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 3/20 0.53
KDM4E B2RXH2 1/20 0.50
RECQL P46063 1/20 0.50
HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4722978 0.92 PTGER1 (0.77) PTGER1LMNARAB9AALDH1A1SMN1; SMN2
SCHEMBL4723747 0.90 PTGER1 (0.70) PTGER1LMNARAB9AALDH1A1SMN1; SMN2
SCHEMBL14098791 0.86 PTGER1 (0.66) PTGER1LMNARAB9AALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL4723620 0.86 PTGER1 (0.65) PTGER1LMNARAB9AALDH1A1SMN1; SMN2
SCHEMBL4723444 0.85 PTGER1 (0.60) PTGER1LMNARAB9AALDH1A1SMN1; SMN2
SCHEMBL5115852 0.85 PTGER1 (0.78) PTGER1LMNARAB9AALDH1A1SMN1; SMN2
SCHEMBL14098793 0.85 PTGER1 (0.65) PTGER1LMNARAB9AALDH1A1SMN1; SMN2
SCHEMBL14098795 0.84 PTGER1 (0.66) PTGER1LMNARAB9AALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL5130803 0.84 PTGER1 (0.67) PTGER1LMNARAB9AALDH1A1SMN1; SMN2
SCHEMBL5124296 0.84 PTGER1 (0.75) PTGER1LMNARAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders GLAXO GROUP LIMITED (GB) 2008-08-28 US disclosed
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders GLAXO GROUP LIMITED (GB) 2008-08-28 US disclosed
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders GLAXO GROUP LIMITED (GB) 2008-08-28 US disclosed
EP-1874776-A1 OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-01-09 EP disclosed
WO-2006114274-A1 OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders PTGER1, PTGER2, PTGER4 PTGER1 1/4885LMNA 2542/4885RAB9A 4378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.